eXoZymes Inc., a biotechnology company focused on developing sustainable biomanufacturing solutions, reported a significant increase in its operating loss for the fiscal year ending December 31, 2025. The company recorded a net loss of $9.2 million, a 56.3% increase from the previous year's loss of $5.9 million. Total operating costs rose to $9.7 million, up 63.8% from $5.9 million in 2024, primarily driven by increased research and development expenses and higher general and administrative costs. The company's cash and cash equivalents decreased by 68.7% to $3.0 million, reflecting a substantial reduction in working capital from $9.5 million in 2024 to $2.4 million in 2025.
In terms of operational developments, eXoZymes has focused on advancing its proprietary technology platform, which utilizes engineered enzymes, termed "exozymes," to produce valuable chemicals sustainably. The company has received a total of $17.7 million in grants since its inception, with $4.1 million awarded in 2025 alone. These grants have been crucial in funding research projects, including work on isobutanol production and cannabinoid synthesis. The company is also in the process of commercializing N-trans-Caffeoyltyramine (NCT), a small molecule with potential applications in treating metabolic disorders, and has established a subsidiary, NCTX, to oversee its commercialization efforts.
eXoZymes has made strategic changes to its organizational structure, including a rebranding effort in February 2025 to clarify its technology focus. The company has expanded its workforce to approximately 32 employees, with plans for further hiring to support its research and development initiatives. The increase in employee headcount and associated costs contributed to the rise in general and administrative expenses, which grew by 47.9% to $6.0 million in 2025.
Looking ahead, eXoZymes anticipates challenges in achieving profitability due to its pre-revenue status and reliance on grant funding. The company has expressed concerns about its ability to continue as a going concern without securing additional financial support. Management is exploring various avenues for funding, including potential partnerships, joint ventures, and licensing agreements, to bolster its financial position and support ongoing operations. The company remains committed to leveraging its technology platform to develop and commercialize innovative biomanufacturing solutions in the nutraceutical and pharmaceutical markets.
About EXOZYMES INC.
eXoZymes Inc. develops cell-free biomanufacturing solutions using engineered enzymes called exozymes, enabled by AI and bioengineering. Its platform produces valuable chemicals for nutraceuticals, pharmaceuticals, and biofuels, offering sustainable, scalable alternatives to traditional petrochemical and synthetic biology methods. The company focuses on licensing, partnerships, and spinouts to commercialize its innovative biosolutions in the biomanufacturing industry.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.